Research
Energy balance
For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo.
Tirzepatide may be beneficial for a broader range of patients, including those with prediabetes.
StrongSupportsmedium confidence
For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo.
Why this rating
The study is a post hoc analysis of a randomized controlled trial.
Source
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the <scp>SURMOUNT</scp> ‐1 trial
Emily R. Hankosky et al. · Diabetes Obesity and Metabolism · 2023
DOI 10.1111/dom.15269
otherCited 42×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide treatment significantly reduced the 10-year predicted risk of developing type 2 diabetes compared with placebo in participants with obesity or overweight.Strong
- At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%).Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →